Overview

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Merit E. Cudkowicz, MD
Collaborator:
Seelos Therapeutics, Inc.